Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Disease	Cell Type	Therapeutic or Technology	Institution	Stage	Project Objective	Details
Brain Cancer, Cancer, Solid Tumors	Somatic Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	UCSF		Pre-IND/IDE or Equivalent
Blood Disorders, IPEX Syndrome	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	ImmunoVec		Pre-IND/IDE or Equivalent
Heart Disease	Adult or Tissue Stem Cell	Antibody, Biologic, Therapeutic Approach	UCLA		Pre-IND/IDE or Equivalent
Neurological Disorders, Stroke	iPS Cell	Donor cell therapy, Therapeutic Approach	PAVIR		Pre-IND/IDE or Equivalent
Cancer, Melanoma, Solid Tumors	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	UCLA		Pre-IND/IDE or Equivalent
Blood Cancer, Cancer, Multiple Myeloma	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	UCLA		Pre-IND/IDE or Equivalent
Brain Injury, hypoxic, ischemic, Neurological Disorders, Pediatrics	Adult or Tissue Stem Cell	Donor cell therapy, Therapeutic Approach	Sanford-Burnham		Pre-IND/IDE or Equivalent
Blood Cancer, Cancer, Multiple Myeloma	Adult or Tissue Stem Cell	Personalized cell therapy, Therapeutic Approach	UCLA		Pre-IND/IDE or Equivalent
Neurological Disorders, Traumatic Brain Injury	Embryonic Stem Cell	Donor cell therapy, Therapeutic Approach	UC Irvine		Pre-IND/IDE or Equivalent
Blood Disorders, Hyper IgM Syndrome, Immune Disease	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	UCLA		Pre-IND/IDE or Equivalent
Age-related macular degeneration, Vision Loss	Adult or Tissue Stem Cell	Donor cell therapy, Therapeutic Approach	Stanford		Pre-IND/IDE or Equivalent
Bladder or Urinary Tract Disorder, Incontinence, Skeletal/Smooth Muscle disorders	iPS Cell	Personalized cell therapy, Therapeutic Approach	Stanford		Pre-IND/IDE or Equivalent
Intestinal Disease, Metabolic Disorders, Neurological Disorders, Pediatrics	iPS Cell	Donor cell therapy, Therapeutic Approach	CHLA		Pre-IND/IDE or Equivalent
Autoimmune Disorder, Lupus, Systemic Lupus Erythematosus (SLE)	iPS Cell	Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	Fate Therapeutics		Clinical Trial, Phase 1 or Phase 1/2
Immune Disease	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	ImmPACT-Bio, Inc.		Clinical Trial, Phase 2
Brain Cancer, Cancer, Solid Tumors		Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	UCSF		Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Parkinson's Disease	iPS Cell	Personalized cell therapy, Therapeutic Approach	Aspen Neuroscience		Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders	Adult or Tissue Stem Cell	Small molecule therapy, Therapeutic Approach	Alto Neuroscience		Clinical Trial, Phase 2
			Allogene Therapeutics
			UCSF
			Luxa Biotechnology
Developmental Disorders, Neurological Disorders, Spina Bifida	Adult or Tissue Stem Cell	Donor cell therapy, Therapeutic Approach	UC Davis		Clinical Trial, Phase 2
Brain Cancer, Cancer, Solid Tumors	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML)		Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	COH		Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Other		Biologic, Nucleic acid based therapy, Therapeutic Approach	UCSD		Clinical Trial, Phase 1 or Phase 1/2
Cancer, Melanoma, Solid Tumors	Somatic Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Age-related macular degeneration, Vision Loss	Embryonic Stem Cell	Donor cell therapy, Therapeutic Approach	Regenerative Patch Technologies LLC		Clinical Trial, Phase 2
HIV/AIDS, Infectious Disease	Other		COH		Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage, Vision Loss	Adult or Tissue Stem Cell	Biologic, Exosomes based therapy, Therapeutic Approach	Combangio		Clinical Trial, Phase 2
Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Neurological Disorders, Vision Loss	Somatic Cell	Personalized cell therapy, Therapeutic Approach	Immusoft Corporation		Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors		Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	Eureka Therapeutics, Inc.		Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders	Adult or Tissue Stem Cell	Antibody, Biologic, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Blood Cancer, Cancer	Somatic Cell	Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	Angiocrine		Clinical Trial, Phase 3
Bone or Cartilage Disease, Osteoarthritis	Somatic Cell	Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach	Genascence Corporation		Clinical Trial, Phase 1 or Phase 1/2
Cancer, Colon Cancer, Solid Tumors			Tachyon Therapeutics, Inc		Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders	Somatic Cell	Cell processing & handling, Immune tolerance/management, Technology	COH		Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders, Bone Marrow Transplant and Viral Infection	Adult or Tissue Stem Cell	Immune tolerance/management, Technology	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Epilepsy, Neurological Disorders	Embryonic Stem Cell	Donor cell therapy, Therapeutic Approach	Neurona Therapeutics		Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS, Infectious Disease		Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach	Excision BioTherapeutics		Clinical Trial, Phase 1 or Phase 1/2
Bladder or Urinary Tract Disorder, Skeletal/Smooth Muscle disorders	Somatic Cell	Technology, Tissue engineering	Wake Forest University Health Sciences		Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, IPEX Syndrome	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	COH		Clinical Trial, Phase 1 or Phase 1/2
Muscle Injury, Skeletal/Smooth Muscle disorders	Adult or Tissue Stem Cell	Personalized cell therapy, Therapeutic Approach	UC Davis		Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors	Adult or Tissue Stem Cell	Personalized cell therapy, Therapeutic Approach	BioEclipse Therapeutics INC.		Clinical Trial, Phase 1 or Phase 1/2
Heart Disease, Heart failure	Embryonic Stem Cell	Donor cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Blood Cancer, Cancer, Leukemia, Leukemia, Acute Myeloid (AML)	Adult or Tissue Stem Cell	Donor cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Stroke	Embryonic Stem Cell	Donor cell therapy, Therapeutic Approach	Stanford		Clinical Trial, Phase 1 or Phase 1/2
Amyotrophic Lateral Sclerosis, Neurological Disorders	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach	Cedars-Sinai		Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors	Adult or Tissue Stem Cell	Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach	COH		Clinical Trial, Phase 1 or Phase 1/2